Nesiritide and clinically relevant outcomes in cardiac surgery: A meta-analysis of randomized studies

Giulia Maj, Giovanni Landoni, Giuseppe Biondi-Zoccai, Elena Bignami, Luca Cabrini, Luca Buratti, Massimiliano Greco, Massimo Zambon, Alberto Zangrillo

Research output: Contribution to journalArticlepeer-review


B-type natriuretic peptide is a cardiac hormone that relaxes vascular smooth muscle and causes arterial dilatation. Nesiritide has been associated with increased urine output; reduced diuretic requirements; and suppression of aldosterone, endothelin, and norepinephrine. We have independently conducted the first systematic review and meta-analysis of randomized trials to determine the impact of nesiritide on renal replacement therapy and death in patients undergoing cardiac surgery. We performed a meta-analysis of 6 randomized controlled studies including 560 patients (280 receiving nesiritide and 280 assigned to the control group). Two unblinded reviewers selected randomized trials studying nesiritide in patients undergoing cardiac surgery. Nesiritide doses ranged from 0.005 mcg/kg/min to 0.01 mcg/kg/min. Nesiritide did not reduce postoperative creatinine peak values: -0.16 [-0.42, 0.10], p for effect=0.23, p for heterogeneity

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalSigna Vitae
Issue number2
Publication statusPublished - 2011


  • Cardiac surgery
  • Meta-analysis
  • Mortality
  • Nesiritide
  • Renal replacement therapy

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine


Dive into the research topics of 'Nesiritide and clinically relevant outcomes in cardiac surgery: A meta-analysis of randomized studies'. Together they form a unique fingerprint.

Cite this